• • IAP-4 induced >90% necrosis in 4T1 cells at 20 µM within 4 h, with selectivity index >10 against normal cells, demonstrating potent oncolytic activity.
• • IAP-4 triggered ICD markers: calreticulin surface exposure increased 8-fold, ATP secretion reached 15 nM, and HMGB1 release was 5-fold higher than control, confirming ICD induction.
• • In vivo, IAP-4 reduced primary tumor volume by 85% and lung metastasis nodules by 90% compared to PBS, with 100% survival over 60 days.
• • IAP-4 treatment increased CD8+ T cell infiltration 6-fold and reduced regulatory T cells by 70% in TME, converting cold to hot tumors.